Biotech & Health Tech
AbbVie, Brise disclose deal for two preclinical migraine meds
AbbVie has agreed to a discovery and commercialization deal with Brise Pharma for two preclinical migraine programs. The Beijing-based partner said Monday the agreement actually stemmed from 2024. An investor relations ...
AbbVie has agreed to a discovery and commercialization deal with Brise Pharma for two preclinical migraine programs. The Beijing-based partner said Monday the agreement actually stemmed from 2024. An investor relations ...
This is a summary of the story. Read the full article at Endpoints News (Biopharma) ↗